MX2023015533A - Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. - Google Patents

Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.

Info

Publication number
MX2023015533A
MX2023015533A MX2023015533A MX2023015533A MX2023015533A MX 2023015533 A MX2023015533 A MX 2023015533A MX 2023015533 A MX2023015533 A MX 2023015533A MX 2023015533 A MX2023015533 A MX 2023015533A MX 2023015533 A MX2023015533 A MX 2023015533A
Authority
MX
Mexico
Prior art keywords
preparation
medicine
application
fused tetracyclic
tetracyclic compound
Prior art date
Application number
MX2023015533A
Other languages
English (en)
Spanish (es)
Inventor
Yang Chen
Feng He
Weikang Tao
Xin Li
Huaide Dong
Feng Shen
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2023015533A publication Critical patent/MX2023015533A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2023015533A 2021-06-21 2022-06-21 Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. MX2023015533A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110687643 2021-06-21
CN202110880105 2021-08-02
CN202111073775 2021-09-14
CN202111225928 2021-10-21
PCT/CN2022/100016 WO2022268051A1 (zh) 2021-06-21 2022-06-21 稠合四环类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2023015533A true MX2023015533A (es) 2024-01-23

Family

ID=84544976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015533A MX2023015533A (es) 2021-06-21 2022-06-21 Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.

Country Status (11)

Country Link
US (1) US20240327434A1 (cg-RX-API-DMAC7.html)
EP (1) EP4361157A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024522766A (cg-RX-API-DMAC7.html)
KR (1) KR20240024903A (cg-RX-API-DMAC7.html)
CN (1) CN117255793B (cg-RX-API-DMAC7.html)
AU (1) AU2022297474A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024646A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220929A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023015533A (cg-RX-API-DMAC7.html)
TW (1) TW202317587A (cg-RX-API-DMAC7.html)
WO (1) WO2022268051A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116867792A (zh) * 2021-02-09 2023-10-10 基因泰克公司 四环氧氮杂䓬化合物及其用途
CN117043167A (zh) 2021-03-17 2023-11-10 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
CN115557974A (zh) * 2021-07-02 2023-01-03 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
CA3226720A1 (en) * 2021-07-23 2023-01-26 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
CN118019746A (zh) * 2021-09-27 2024-05-10 北京加科思新药研发有限公司 多环稠环衍生物及其用途
JP2025504041A (ja) * 2022-01-30 2025-02-06 シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド キノリン系化合物及びその使用
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
CN119365467A (zh) * 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
KR20250034087A (ko) * 2022-07-09 2025-03-10 블로썸힐 테라퓨틱스, 인크. 질병 치료를 위한 융합 고리 kras 억제제
TW202409051A (zh) * 2022-07-27 2024-03-01 大陸商江蘇恆瑞醫藥股份有限公司 稠環類化合物、其製備方法及其在醫藥上的應用
KR20250037564A (ko) * 2022-07-29 2025-03-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Kras g12d 억제제를 포함하는 약학적 조성물
CN119585278A (zh) * 2022-08-05 2025-03-07 杭州中美华东制药有限公司 具有KRas G12D抑制作用的化合物
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024041573A1 (en) * 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
TW202426459A (zh) * 2022-09-23 2024-07-01 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
TW202440594A (zh) * 2022-12-07 2024-10-16 大陸商北京加科思新藥研發有限公司 稠環化合物及其用途
TW202430184A (zh) * 2022-12-20 2024-08-01 大陸商江蘇恒瑞醫藥股份有限公司 Kras g12d抑制劑的結晶形式及製備方法
WO2024149214A1 (en) * 2023-01-10 2024-07-18 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
WO2024159471A1 (en) * 2023-02-02 2024-08-08 Nikang Therapeutics , Inc. Tetracyclic derivatives as kras inhibitors
WO2024234360A1 (en) * 2023-05-18 2024-11-21 Nikang Therapeutics , Inc. Tetracyclic derivatives as kras inhibitors
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2024208305A1 (zh) * 2023-04-07 2024-10-10 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
WO2024213979A1 (en) * 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) * 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
JP2026522894A (ja) * 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
JP2026523268A (ja) 2023-07-13 2026-07-13 上海森▲輝▼医▲葯▼有限公司 Kras g12d中間体の調製方法
CN121843945A (zh) * 2023-07-18 2026-04-10 泰励生物科技(上海)有限公司 具有抗kras突变肿瘤活性的化合物
WO2025045141A1 (en) * 2023-08-31 2025-03-06 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
CN122228262A (zh) * 2023-11-02 2026-06-16 金橘生物科技公司 降解剂及其用途
WO2025108443A2 (en) * 2023-11-23 2025-05-30 Beigene Switzerland Gmbh Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2025146194A1 (en) * 2024-01-05 2025-07-10 Jacobio Pharmaceuticals Co., Ltd. Fused tetracyclic compounds and use thereof
AU2025209726A1 (en) * 2024-01-17 2026-07-09 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
CN119684315B (zh) * 2024-01-26 2026-05-12 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
WO2025157261A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物晶型及其制备方法
CN119490512B (zh) * 2024-01-26 2026-06-16 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119661555B (zh) * 2024-01-26 2026-04-14 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2018206539A1 (en) 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
CN110869358A (zh) * 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN113874374B (zh) 2019-05-24 2024-12-27 江苏恒瑞医药股份有限公司 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2021000885A1 (zh) 2019-07-01 2021-01-07 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
CN114615981B (zh) * 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CN116867792A (zh) * 2021-02-09 2023-10-10 基因泰克公司 四环氧氮杂䓬化合物及其用途
US20240199644A1 (en) * 2021-03-07 2024-06-20 Jacobio Pharmaceuticals Co., Ltd. Fused Ring Derivatives Useful as KRAS G12D Inhibitors
CN117043167A (zh) * 2021-03-17 2023-11-10 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
WO2022206723A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
CN115557974A (zh) * 2021-07-02 2023-01-03 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
CA3226720A1 (en) * 2021-07-23 2023-01-26 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
WO2023025116A1 (zh) * 2021-08-25 2023-03-02 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
JP2025504041A (ja) * 2022-01-30 2025-02-06 シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド キノリン系化合物及びその使用
EP4511127A1 (en) * 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN119365467A (zh) * 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途

Also Published As

Publication number Publication date
EP4361157A4 (en) 2024-10-16
KR20240024903A (ko) 2024-02-26
EP4361157A1 (en) 2024-05-01
TW202317587A (zh) 2023-05-01
WO2022268051A1 (zh) 2022-12-29
CN117255793B (zh) 2026-06-12
CA3220929A1 (en) 2022-12-29
BR112023024646A2 (pt) 2024-03-05
US20240327434A1 (en) 2024-10-03
JP2024522766A (ja) 2024-06-21
AU2022297474A1 (en) 2024-01-18
CN117255793A (zh) 2023-12-19

Similar Documents

Publication Publication Date Title
MX2025001020A (es) Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinal
BR112023024646A2 (pt) Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina
ZA202308118B (en) Cdk inhibitor
MX2023001980A (es) Derivado de imidazol fusionado, metodo de preparacion y uso medico del mismo.
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
MX2024004846A (es) Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
JOP20220271A1 (ar) مركبات دايازينو بيريميدين كمثبطات لـ her2
NZ777871A (en) Small molecule modulators of il-17
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
MX2025001619A (es) Inhibidor de pde4b y uso del mismo
MX2025009943A (es) Derivado de camptotecina, su conjugado, su metodo de preparacion y su uso medico
ZA202309638B (en) Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
NZ627274A (en) Anesthetic compounds and related methods of use
ZA202102155B (en) Nitroxoline prodrug and use thereof
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
ZA202400988B (en) Aak1 inhibitor and use thereof
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2026001837A (es) Compuestos que contienen ciclobutilo